-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Advanced prostate cancer kills over 11,500 people each year in the UK alone
Advanced Accelerator Applications (AAA), a Novartis pharmaceutical company, has announced that eligible patients with advanced prostate cancer in the UK have been approved for early-stage radioligand therapy
Lutetium (177Lu) vipivotide tetraxetan is a radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA) targeting ligand, bound to the beta-emitting radioisotope lutetium (177Lu) with antitumor activity
The decision to approve lutetium(177Lu) vipivotide tetraxetan was supported by an international, prospective, open-label, multicenter, randomized, phase III study (VISION; NCT03511664)
At a median follow-up of 20.
The median OS was 15.
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://